Biotech Values

[ghmm]

I was aware of the allowable therapies my concern was more from the wide variety of therapies leading to a more customized therapy for each patient and things that are becoming more available like tumor genotyping could in some (perhaps very few) cases put the treatment arm at an actual disadvantage.

In the case of 102 I actually thought one benefit would be the ability to combine it with other treatments (another reason for the company to have partnered).

BTW I am long NKTR.